Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial

ConclusionsThe long-term effectiveness and safety/tolerability of eptinezumab in patients with migraine and 2 –4 prior preventive treatment failures was demonstrated by high completion rates and migraine-preventive benefits sustained for up to 18 months, implying that eptinezumab is a viable long-term treatment option for patients still seeking successful migraine treatments.Trial registrationClinicalTrials.gov (Identifier: NCT04418765; URL:https://www.clinicaltrials.gov/ct2/show/NCT04418765); EudraCT (Identifier: 2019-004497-25; URL:https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004497-25).Graphical Abstract
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research